The prospectus relates to the proposed resale or disposition of an aggregate of 9,108,836 shares of common stock. KBL last year merged with pharma company 180 Parties. Shares in KBL trade on the NASDAQ under the symbol “KBLM.” Read more.
Related Posts
Alpha Healthcare Sets Vote Date on $1.1B Humacyte Deal
Humacyte is expected to receive up to $275 million in gross proceeds.
Rodgers Silicon Valley Acquisition Files Proxy on $1.13B Enovix Deal
Terms call for Enovix to receive $385 million in net cash, after expenses consisting of approximately $230 million cash held in trust by the SPAC and a $175 million concurrent PIPE of common stock issued at $14 per share.
Zanite Files Definitive Prospectus on $200M IPO
The SPAC is focused on companies in the aviation, aerospace and defense, urban mobility and emerging technologies industries.
NextGen Acquisition Files Prelim Proxy on $2B Xos Deal
The transaction will provide $575 million of gross proceeds to the company, assuming no redemptions, including a $220 million oversubscribed and fully committed common stock PIPE.